Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03003468 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Lawrence Feldman, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 5
- Study locations
NCT03003468 is a Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by Lawrence Feldman, MD. The registered enrollment target is 35 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03003468, a Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by Lawrence Feldman, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
Conditions Studied
Interventions
- DRUG MK-3475
- DRUG Imprime PGG
Study Locations (5)
Illinois
- University of Illinois at Chicago - Chicago
Indiana
- Indiana Univeristy Melvin and Bren Simon Cancer Center - Indianapolis
Iowa
- University of Iowa Hospital and Clinics - Iowa City
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Pennsylvania
- Penn State Cancer Institute - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-07-11 |
| Est. Completion | 2022-11-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03003468
The ClinicalTrials.gov registry entry for NCT03003468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Lawrence Feldman, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which MK-3475 is the first listed.
NCT03003468 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Indiana, Iowa.
Frequently Asked Questions
What is clinical trial NCT03003468 about?
NCT03003468 is a clinical study titled "Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017". This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
What is the current status of trial NCT03003468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2017-07-11. Estimated completion is 2022-11-28.
What conditions does trial NCT03003468 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03003468?
The interventions under investigation include: MK-3475 (DRUG), Imprime PGG (DRUG).
Who is sponsoring clinical trial NCT03003468?
This trial is sponsored by Lawrence Feldman, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03003468 being conducted?
This trial has 5 study locations across Illinois, Indiana, Iowa, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.